

NEW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Santosh R. D'Mello, et al.

Serial No.: 10/688,759

Filing Date: October 17, 2003

Art Unit: 1653

For: The Use of C-Raf
Inhibitors for the Treatment
of Neurodegenerative
Diseases

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:	
<u>December 28, 2005</u>	
(Date of Mailing)	
<u>Janice Schigut</u>	
(Name of Person Mailing Document)	
<u>Janice Schigut</u>	
(Signature)	

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §1.56, Applicant submits this statement. This submittal is made in accordance with 37 C.F.R. §§1.97 and 1.98 and §609 of the Manual of Patent Examining Procedure. The disclosed information is listed on the attached Form PTO-1449.

Applicant hereby expressly reserves the right to swear behind the effective dates of the listed published patent applications and to question their relevance and materiality, in whole, in part, or in combination, subsequent to filing this Information Disclosure Statement.

It is believed no fee is due for submission of this paper. If this is incorrect, the Commissioner is hereby authorized to charge any fee due to Locke Liddell & Sapp LLP Deposit Account No. 12-1781.

Respectfully submitted,

By: 
Scott C. Sample
Registration No. 52,189

Date: December 28, 2005

LOCKE LIDDELL & SAPP LLP
2200 Ross Avenue, Ste. 2200
Dallas, TX 75201-6776
(214) 740-8489
(214) 740-8800 (fax)



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Complete if Known

Application Number	10/688,759
Filing Date	October 17, 2003
First Named Inventor	Santosh R. D'Mello
Art Unit	1653
Examiner Name	Unassigned
Attorney Docket Number	91556.00003

Sheet	1	of	1
-------	---	----	---

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.